<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1939">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381286</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0194</org_study_id>
    <nct_id>NCT04381286</nct_id>
  </id_info>
  <brief_title>Transpulmonary Driving Pressure in ARDS COVID19 Patients</brief_title>
  <acronym>TRANSPULMONARY</acronym>
  <official_title>Transpulmonary Driving Pressure in ARDS COVID19 Patients / TRANSPULMONARY-COVID19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A majority (65-85%) of critically ill patients admitted in intensive care units with a
      confirmed diagnostic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
      developed an acute respiratory distress syndrome (ARDS) according to BERLIN criteria.
      Gattinoni et al. recently described that the ARDS related to SARS-CoV-2 was not a &quot;Typical&quot;
      ARDS. Patients affected by this infection present indeed a major hypoxemia, which was
      surprisingly associated in early phase with a high compliance of respiratory system, more
      than 50 ml/cm H2O in most cases. The cornerstone of current treatment in case of ARDS is the
      use of &quot;lung protective&quot; ventilation, including limited tidal volumes (VT), low
      end-inspiratory plateau pressures while maintaining sufficiently-high positive end-expiratory
      pressures (PEEP). However, high levels of PEEP in patients may have detrimental effects on
      hemodynamic status and fluid retention, particularly when the respiratory system compliance
      is normal. High PEEP may also lead to overdistension and an increase of alveolar dead space.
      The airway pressures commonly monitored does not reliably reflect the impact of pressures on
      the lung parenchyma. Elastance of chest wall may indeed largely influence values of airways
      pressions. In contrast, transpulmonary pressure obtained using esophageal pressure (Pes)
      directly reflect lung overdistension risk and lung properties. In order to better understand
      this new kind of ARDS characterized by modest recruitable profile and to better personalize
      mechanical ventilation setting and therapy it is obvious to precise transpulmonary pressure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of mechanical Ventilation</measure>
    <time_frame>1 day</time_frame>
    <description>Duration of mechanical Ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with during of Acute respiratory distress syndrom (SDRA)</measure>
    <time_frame>1 day</time_frame>
    <description>Number of Participants with during of Acute respiratory distress syndrom (SDRA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care unit</measure>
    <time_frame>1 day</time_frame>
    <description>Length of stay in intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 day</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with pulmonary complications</measure>
    <time_frame>1 day</time_frame>
    <description>number of patients with pulmonary complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with pulmonary stress and strain</measure>
    <time_frame>1 day</time_frame>
    <description>Number of Participants with pulmonary stress and strain</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mechanical Ventilation</condition>
  <condition>SARS-CoV-2</condition>
  <condition>COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with SARS-CoV-2 and mechanical ventilation requirement
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Major patients (18-90 years old)

          -  Hospitalized following SARS-CoV-2

          -  Mechanical ventilatory support

        Exclusion criteria:

          -  Minor patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramin Séverin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramin Séverin, MD</last_name>
    <phone>46733825</phone>
    <phone_ext>33</phone_ext>
    <email>s-ramin@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramin SEVERIN, MD</last_name>
      <phone>467338256</phone>
      <phone_ext>33</phone_ext>
      <email>o-choquet@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 10, 2020</last_update_submitted>
  <last_update_submitted_qc>May 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>elastance</keyword>
  <keyword>Acute respiratory distress syndrome</keyword>
  <keyword>Esophageal pressure</keyword>
  <keyword>Pleural pressure</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

